Striding toward a cure for pancreatic cancer
May 3, 2016 | by City of Hope
Pancreatic cancer is now the third-leading cause of cancer-related deaths in the country. This means more individuals will die from pancreatic cancer this year than from breast cancer.
The most common reason?
Pancreatic cancer rarely shows symptoms in its early stages, so it’s often detected when the disease is advanced and difficult to treat. While the five-year survival rate for pancreatic cancer has increased slightly in recent years, thanks to advancements in research and treatment, at 8 percent its survival rate remains the lowest of any of the major cancers, according to the Pancreatic Cancer Action Network (also known as PanCan.)
Of course, there is hope: For patients struggling with pancreatic cancer, aggressive therapies and a dedicated multidisciplinary team such as those offered City of Hope, make improved outcomes possible.
Scientific research breakthroughs are also integral in bringing about better treatments, and a cure.
To help advance this national effort, City of Hope will be participating in PanCan’s annual PurpleStride event on May 7, a 5k walk/run at Exposition Park in Los Angeles that draws tens of thousands supporters in 56 separate events nationwide. By participating, City of Hope and its team of runners, the City of Hope Striders, will help to raise much-needed awareness of this deadly disease.
“These events are critical in raising awareness and funds that advance research and support patients and loved ones,” says Susanne Gray Warner, M.D., assistant clinical professor in the Department of Surgery, and a member of the City of Hope Striders.
“PanCan is a wonderful organization that provides excellent patient support, grant funding and patient enrollment in clinical trials. I hope we can have strong representation from our team,” she added.
If you are looking for a second opinion or consultation about your treatment, request an appointment online or contact us at 800-826-HOPE. Please visit Making Your First Appointment for more information.